Saudi Arabia’s General Authority for Military Industries Announces a Fully Integrated Defense Show Starting March 2022
17.7.2020 00:05:00 EEST | Business Wire | Press release
Today the Kingdom of Saudi Arabia’s General Authority for Military Industries (GAMI) announced the launch of ‘World Defense Show’. The show will take center stage in the global defense show circuit, offering exhibitors and visitors the opportunity to participate in Saudi Arabia’s first truly integrated defense show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716006046/en/
His Excellency Ahmad Al Ohali, Governor of GAMI (Photo: AETOSWire)
Founded by GAMI, World Defense Show is focused on interoperability across air, land, sea, security innovative defense technologies and satellite defense systems. The inaugural event is scheduled to take place between 6th and 9th March 2022 and will then be held biennially in Saudi Arabia’s capital, Riyadh.
Speaking at a virtual press conference attended by international defense companies, GAMI’s Governor, His Excellency Ahmad Al Ohali stated: “As Technology is accelerating the rate at which the global defense industry is evolving, defense considerations are becoming increasingly complex. There is a need for a platform, which enables the defense community to convene and collectively consider the great opportunities and challenges that are facing us all. This is why we are launching World Defense Show, an innovative platform showcasing, through both live and virtual demonstrations, the possibilities that interoperability can provide across all five defense domains: Air, Land, Sea, Security and Satellite.”
He added, “There is no better place than Saudi Arabia to organize a defense event at this scale. A G20 country, the Kingdom is one of the world’s biggest defense spenders with a strategic location at the center of three continents, making it an ideal hub for defense trade and innovation. Saudi Arabia’s vision to localize 50% of its multi-billion-dollar defense expenditure by 2030 also presents massive opportunities to global industry OEMs and investors.”
GAMI has recruited a team of international experts to organize and run event operations.
Shaun Ormrod, Chief Executive Officer, World Defense Show, said: “Today’s launch of World Defense Show marks an exciting inflection point for the defense industry and a step forward in the ambition and scale of a defense trade show. Through World Defense Show we will demonstrate why Saudi Arabia is critical to the defense industry’s future. The platform will enable access to dedicated programs that support Saudi Arabia’s local businesses, it will leverage investment opportunities and encourage a new generation to aspire to work in the defense industry.” Mr. Ormrod is the former CEO of Farnborough Airshow with over 20 years of industry trade show expertise.
Over four days, World Defense Show will showcase comprehensive and interactive displays of integrated defense technology solutions, alongside conferences and thought leadership seminars focused on the next generation of defense. The show’s venue, estimated to accommodate 80,000 square meters of exhibition, hospitality and outdoor area, will feature demonstration facilities and virtual technological capabilities to showcase every defense domain on an unprecedented scale.
Video News Release embed and download link here
About World Defense Show
World Defense Show is a display and demonstration of integrated and innovation-driven defense solutions, set to serve as the global stage for defense interoperability. The inaugural World Defense Show will take place biannually starting March 2022 in Riyadh - Saudi Arabia, to showcase the latest in interoperable defense solutions. The event will be held in the presence of Saudi Arabia’s key leadership, international delegations and prominent industry decision makers from around the world.
About General Authority for Military Industries
The founder of World Defense Show, Saudi Arabia’s General Authority for Military Industries, is the regulator, enabler and licensor for the kingdom’s military industry. GAMI is responsible for domestic defense sector development in line with the national commitment to localize 50% of military manufacturing by 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716006046/en/
Contact information
Yara Abifaker, +971544285342
yara.abifaker@finsbury.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom